CAR-T Followed by Bispecific Antibodies
Not Recruiting
18-99 years
All
Phase
2
40 participants needed
1 Location
Brief description of study
The research study is being conducted to test the safety and effectiveness of the experimental drug mosunetuzumab or obinutuzumab and glofitamab (Cohort 2) when given after CAR (genetically modified) T cells. The study is for patients who have already received a CAR T-cell infusion. Some patients who join the study will receive mosunetuzumab, other patients later in the study may receive a different experimental drug (glofitamab, in combination with obinutuzumab).
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Large B-cell Lymphoma
-
Age: Between 18 Years - 99 Years
-
Gender: All
Male or Female, Age 18 or older Life expectancy of at least 12 weeks, History of relapsed or refractory DLBCL, HGBCL, PMBCL or tFL who have relapsed after or failed to respond to at least two prior standard systemic treatment regimens
Updated on
11 Sep 2024.
Study ID: 844799